A Nanotechnology Patch for Early-Stage Oral Cancer
Official title: Support for Registration Enabling Phase 3 Clinical Trial for Nanotechnology-Based Treatment of Carcinoma in Situ of the Oral Cavity (Stage 0 Oral Cancer)
Funded at Privo Technologies, LLC · NIH-11116997 · Data updated 2026-11-12
This project supports a late-stage clinical trial for a new topical patch designed to treat early-stage oral cancer.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Privo Technologies, LLC NIH-funded |
| Lab location | 1 site (Peabody, United States) |
| Project start | June 14, 2024 |
| Project end | May 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $1,245,681 |
| NIH project number | 5R44CA281020-08 |
| Project ID | NIH-11116997 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates would be patients diagnosed with Carcinoma in Situ of the Oral Cavity, also known as Stage 0 oral cancer.
✕Less likely to help
Patients with more advanced stages of oral cancer or other types of cancer would likely not benefit from this specific topical treatment.
What this research studies
This grant focuses on a Phase 3 clinical trial for PRV111, a topical chemotherapy patch for Carcinoma in Situ of the Oral Cavity, also known as Stage 0 oral cancer. Current treatments for oral cancer often involve extensive surgery, which can lead to severe and permanent side effects like speech impairment, difficulty swallowing, and facial disfigurement. This new patch aims to deliver a chemotherapy drug directly to the tumor using tiny nanoparticles, potentially avoiding the need for such invasive procedures. The patch is designed to stick to the affected area and release the medication locally, offering a less invasive treatment option for patients.
Why it matters
Potential benefit: If successful, this treatment could offer patients with early oral cancer a less invasive option that avoids the devastating side effects of surgery, significantly improving their quality of life.
How similar studies have gone: This nanotechnology-based topical delivery system is a novel approach for oral cancer, building upon the established use of chemotherapy drugs.
Where this research is happening
-
Privo Technologies, LLC
Peabody, United States Active
Researchers
- Principal investigator: Goldberg, Manijeh N — Privo Technologies, LLC
- Study coordinator: Goldberg, Manijeh N
Related research
Other NIH-funded projects on the same topics.
-
Topical chemotherapy patch for early oral cancer (Stage 0) to support a phase 3 trial
A new topical patch delivering chemotherapy directly to the tumor is being tested to help people with very early oral cancer.
-
Novel idea: Epstein-Barr virus and eye cancer in people living with HIV in Zimbabwe
A study explores whether Epstein-Barr virus could cause a type of eye cancer in people living with HIV in Zimbabwe.
-
Glutamine and macrophage behavior in liver cancer
A funded project at a medical university aims to understand how the liver’s immune cells interact with a specific type of liver cancer by looking at metabolism, especially glutamine and ammonia.
-
Understanding bladder cancer biology to find new biomarkers and therapies
A study at Tuskegee University will look at the molecules inside high-grade bladder cancer to discover new markers and potential treatment targets.
-
Mobile platform using AI to screen for oral cancer in low-resource communities
A low-cost, AI-powered mobile tool helps frontline healthcare workers screen for oral cancer and triage patients in communities with limited access to specialists.
-
Endosomal signaling and cancer pain control in oral cancer
A study to understand how signals inside nerve cells and supportive cells contribute to pain in people with oral cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.